Ken Griffin Heron Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$1.73 - $3.67 $2,941 - $6,239	1,700 Added 4.42%	40,200 $79,000
Q2 2024 Aug 14, 2024	BUY	$2.32 - $3.86 $41,528 - $69,094	17,900 Added 86.89%	38,500 $134,000
Q1 2024 May 15, 2024	SELL	$1.71 - $3.06 $104,823 - $187,578	-61,300 Reduced 74.85%	20,600 $57,000
Q4 2023 Feb 14, 2024	BUY	$0.54 - $1.82 $38,124 - $128,492	70,600 Added 624.78%	81,900 $139,000
Q3 2023 Nov 14, 2023	SELL	$0.97 - $1.8 $4,947 - $9,180	-5,100 Reduced 31.1%	11,300 $11,000
Q2 2023 Aug 14, 2023	BUY	$1.11 - $2.88 $9,102 - $23,616	8,200 Added 100.0%	16,400 $19,000
Q1 2023 May 15, 2023	SELL	$1.51 - $3.25 $16,610 - $35,750	-11,000 Reduced 57.29%	8,200 $12,000
Q4 2022 Feb 14, 2023	SELL	$2.25 - $4.67 $50,175 - $104,141	-22,300 Reduced 53.73%	19,200 $48,000
Q3 2022 Nov 14, 2022	BUY	$2.66 - $5.37 $80,598 - $162,711	30,300 Added 270.54%	41,500 $175,000

181

121M

80.4K

94.9K

Ticker HRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,774,000
Market Cap $141M
Description
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.